Servier Acquires Day One
- Servier finalized its acquisition of Day One Biopharmaceuticals, expanding its oncology portfolio including tovorafenib OJEMDA™. - The deal brings clinical candidates and commercial planning responsibilities that may trigger regulatory and commercial systems RFPs. - Vendors supporting R&D IT, pharmacovigilance, and launch enablement should expect integration and procurement cycles. (prnewswire.com)
Servier said Thursday it has completed its acquisition of Day One Biopharmaceuticals, bringing the pediatric brain tumor drug OJEMDA into its oncology business. (mma.prnewswire.com) The deal closed after Servier’s tender offer for Day One shares expired at 11:59 p.m. Eastern on April 22, 2026, and the buyer accepted tendered shares at $21.50 each. Servier valued the transaction at about $2.5 billion when the companies announced it on March 6. (mma.prnewswire.com) (ir.dayonebio.com) Day One’s main commercial asset is OJEMDA, the brand name for tovorafenib, which the Food and Drug Administration approved in 2024 for children 6 months and older with relapsed or refractory low-grade glioma tied to specific BRAF alterations. The label says the drug is taken once weekly and was cleared under the agency’s accelerated approval pathway. (accessdata.fda.gov) Low-grade glioma is the most common childhood brain tumor, and Servier said the acquisition strengthens its position in that market. Day One had already been selling OJEMDA in the United States before the takeover closed. (mma.prnewswire.com) (dayonebio.com) The purchase also gives Servier a broader pipeline than a single marketed drug. In Thursday’s closing announcement, Servier said Day One adds clinical-stage assets ranging from early development through Phase 3, including Emi-Le, an antibody-drug conjugate, and DAY301, a targeted therapy for rare cancers. (mma.prnewswire.com) That pipeline had grown even before the acquisition closed. Day One told investors in February that OJEMDA generated $155.4 million in net product revenue in 2025 and said its January 2026 acquisition of Mersana Therapeutics added Emi-Le to the portfolio. (biospace.com) The structure matters for what changes next. Day One entered the merger agreement with Servier Pharmaceuticals LLC and Servier Detroit Inc. on March 6, with the transaction set up as a tender offer followed by a merger under Delaware law. (sec.gov) Commercial operations will not be confined to the United States. Servier said Day One already markets OJEMDA in the U.S., while rights outside the U.S. have been licensed to Ipsen. (mma.prnewswire.com) For Servier, the close turns a March agreement into an operating business with an approved pediatric cancer medicine, an active launch infrastructure, and late- and early-stage oncology programs to absorb. (ir.dayonebio.com) (mma.prnewswire.com)
